Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
99 results about "Integrin antagonist" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Integrin Antagonists Drug Class. Overall, Integrin antagonists help promote healthy tissue development, development of the immune response, homeostasis, monitoring/slowing down tumor cell growth, inflammation and angiogenesis.
Integrin antagonists with enhanced antibody dependent cell-mediated cytoxicity activity
InactiveUS20060040325A1Enhance ADCCAltered binding affinityCompound screeningApoptosis detectionIntegrin antagonistComplement-dependent cytotoxicity
The present invention relates to novel Fc variants of antibodies that immunospecifically binds to Integrin αvβ3. The Fc variants comprise a variable region that immunospecifically binds to Integrin αvβ3 and a Fc region that further comprises at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more FcγR and / or C1q. Additionally, the Fc variants have altered antibody dependent cell-mediated cytotoxicity (ADCC) and / or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants of an antibody that immunospecifically binds to Integrin αvβ3, particularly for therapeutic purposes.
Owner:MEDIMMUNE LLC
Use of integrin antagonists to inhibit angiogenesis
InactiveUS7074408B2Inhibit biological activityInhibit cell migrationAntibacterial agentsSenses disorderDiseaseIntegrin antagonist
The present invention provides methods and compositions for inhibiting the biological activity of integrins, for inhibiting endothelial cell migration. and for inhibiting angiogenesis. In particular, the invention provides compositions comprising ADAM disintegrin domains and methods for using said compositions. In preferred embodiments the methods and compositions of the invention are used to inhibit angiogenesis and to treat diseases or conditions mediated by angiogenesis.
Owner:IMMUNEX CORP
Method for augmenting B cell depletion
InactiveUS20050276803A1Good curative effectEnhance B cell depletionOrganic active ingredientsNervous disorderIntegrin antagonistBlood vessel
The present invention provides methods of augmenting B cell depletion by promoting intravascular access of B cell subsets sequestered in lymphoid tissues rendering the B cells sensitive to killing mediated by the B cell depleting agent. One method of promoting intravascular access is by the use of integrin antagonists. Methods of treating B cell disorders by this approach is also provided.
Owner:GENENTECH INC
Alfavbeta3 and alfavbet6 integrin antagonists as antifibrotic agents
InactiveUS20070117849A1Prevent and mitigate and even reverse developmentEasy to prepareBiocideDigestive systemIntestinal structureCTGF
This invention relates to inhibition of αv integrins, especially αvβ3 and αvβ6 integrins, by specific antagonists, preferably non-peptidic antagonists, related compounds and compounds with comparable specificity, that downregulate fibrogenesis by inhibiting cell migration and production of pro-fibrogenic molecules (e.g., collagens, TIMP-1) and cytokines (e.g., CTGF) by activated hepatic stellate cells / myofibroblasts, activated epithelia and endothelia. These antagonists alone or in combination with other agents can effectively prevent, mitigate or even reverse development of advanced fibrosis, such as fibrosis / cirrhosis of the liver and fibrosis of other organs, such as lungs, kidneys, intestine, pancreas, skin and arteries.
Owner:MERCK PATENT GMBH
Delivery system for nucleic acids
Owner:THE SCRIPPS RES INST +1
Method for Augmenting B Cell Depletion
InactiveUS20080075719A1Good curative effectIncrease lossOrganic active ingredientsNervous disorderDiseaseIntegrin antagonist
The present invention provides methods of augmenting B cell depletion by promoting intravascular access of B cell subsets sequestered in lymphoid tissues rendering the B cells sensitive to killing mediated by the B cell depleting agent. One method of promoting intravascular access is by the use of integrin antagonists. Methods of treating B cell disorders by this approach is also provided.
Owner:GENENTECH INC
3,5 Phenyl-Substituted Beta Amino Acid Derivatives as Integrin Antagonists
Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula:wherein X is bromo or iodo, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.
Owner:SAINT LOUIS UNIVERSITY
Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
InactiveUS7211252B2Halting progressive bone destructionImprove the quality of lifeImmunoglobulin superfamilyPeptide/protein ingredientsIntegrin antagonistIntegrin ligand
Antagonists of alpha 4 integrin / alpha 4 integrin ligand adhesion, which inhibit the biological effects of such adhesion are described and methods for their use are detailed. Such antagonists are useful in suppressing bone destruction associated with multiple myeloma. The homing of multiple myeloma cells to bone marrow and their alpha 4 integrin-dependent release of bone-resorbing factors, resulting in bone destruction in patients with multiple myeloma, is inhibited.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
A compound of formula (I) or a salt thereofwhereinR1 represents a hydrogen atom, a methyl group or a ethyl groupR2 represents a hydrogen atom or a fluorine atomR3 represents a hydrogen atom, a methyl group or an ethyl group.
Owner:GLAXOSMITHKLINE INTPROP DEV LTD
Integrin antagonists useful as anticancer agents
InactiveUS20060116383A1Ease of detectabilityEasy to prepareBiocideOrganic chemistryDiseaseIntegrin antagonist
The invention relates to compounds of the Formula 1 and to pharmaceutically acceptable salts and solvates thereof, wherein A, X2, X4, X5 and X1 are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of Formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of Formula 1.
Owner:ALCATEL LUCENT SAS
Beta Amino Acid Derivatives as Integrin Antagonists
ActiveUS20140038910A1Sufficient amountToxic reductionBiocideUrea derivatives preparationIntegrin antagonistFibrosis
Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula:wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.
Owner:SAINT LOUIS UNIVERSITY
Fluorinated integrin antagonists
The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
Owner:OCUTERRA THERAPEUTICS INC
Fluorinated integrin antagonists
The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
Owner:OCUTERRA THERAPEUTICS INC
Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
The present invention relates to methods for treating multiple sclerosis by administering therapeutically effective amounts of an alpha-fetoprotein polypeptide (or a biologically active fragment, derivative, or analog thereof) and an integrin antagonist (e.g., natalizumab) to a patient in need thereof. Also disclosed are compositions and kits that comprise therapeutically effective amounts of an alpha-fetoprotein polypeptide (or a biologically active fragment, derivative, or analog thereof) and an integrin antagonist (e.g., natalizumab).
Owner:MERRIMACK PHARMACEUTICALS INC
Substituted indoles and their use as integrin antagonists
The present invention relates to novel substituted indole compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by αvβ3 and αvβ5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.
Owner:3 DIMENSIONAL PHARMA
NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS
Owner:GLAXOSMITHKLINE INTPROP DEV LTD
3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
ActiveUS8716226B2Organic chemistryPeptide/protein ingredientsIntegrin antagonistAngiogenesis growth factor
Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula:wherein X is bromo or iodo, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.
Owner:SAINT LOUIS UNIVERSITY
Prevention or Treatment of Cancer Using Integrin alphavbeta3 Antagonists in Combination with Other Agents
InactiveUS20090148459A1Improve efficiencyImprove toleranceOrganic active ingredientsPeptide/protein ingredientsCancer preventionOncology
Owner:WOESSNER RICHARD +4
Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
InactiveUS20100183599A1Immunoglobulin superfamilyPeptide/protein ingredientsIntegrin antagonistCancer research
Antagonists of α4 integrin / α4 integrin ligand adhesion, which inhibit the biological effects of such adhesion are described and methods for their use are detailed. Such antagonists are useful in suppressing bone destruction associated with multiple myeloma. The homing of multiple myeloma cells to bone marrow and their α4 integrin-dependent release of bone-resorbing factors, resulting in bone destruction in patients with multiple myeloma, is inhibited.
Owner:MUNDY GREGORY R +1
Integrin antagonist conjugates for targeted delivery to cells expressing lfa-1
The invention relates to compounds of formula I:wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula I for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to LFA-1 integrin antagonists to target cells expressing LFA-1.
Owner:F HOFFMANN LA ROCHE & CO AG
Method for indentifying integrin antagonists
InactiveUS20050227296A1Controlling phagocyte-mediated tissue damageReduce perfusionCompound screeningApoptosis detectionIntegrin antagonistChemistry
Owner:THE GENERAL HOSPITAL CORP
Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3
ActiveUS20150038523A1Reduce deliveryUrea derivatives preparationBiocideBeta IntegrinsIntegrin antagonist
The invention relates to compounds of formula (I): wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula (I) for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to alpha-V-beta-integrin antagonists to target cells expressing alpha-V-beta-3.
Owner:F HOFFMANN LA ROCHE & CO AG
Polyethylene glycol-modified integrin blocker hm-3 and use thereof
InactiveUS20140329759A1Positive roleEconomic valueConnective tissue peptidesPeptide/protein ingredientsIntegrin antagonistPolyethylene glycol
The present invention involves the pharmaceutical field, including integrin antagonists, which have the capacities of inhibiting angiogenesis of tumors, binding integrin. These antagonists are a kind of polypeptide, which was modified by polyethylene glycol and after modification, it can be used to treat tumors. The sequence and structure of these antagonists is mPEG-SC20k-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp, which demonstrates it is scientific, reasonable and feasible in tumor treatment and greatly expands the treatment spectrum. It can provide new ideas and perspectives for drug development and has significant social and market value.
Owner:XU HANMEI
Delivery system for nucleic acids
InactiveUS7025987B2Accelerated destructionOrganic active ingredientsBiocideAmphiphileIntegrin antagonist
αvβ3 Integrin receptor targeting liposomes comprise a cationic amphiphile such as a cationic lipid, a neutral lipid, and a targeting lipid. The targeting lipid includes a non-peptidic αvβ3 integrin antagonist.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV +1
Beta amino acid derivatives as integrin antagonists
Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula:wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.
Owner:SAINT LOUIS UNIVERSITY
Continuous administration of cilengitide in cancer treatments
InactiveUS20120130146A1Prolonged progression-free survivalProlong median survivalAntibacterial agentsOrganic active ingredientsEfficacyIntegrin ligand
The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising the continuous administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agent or therapy forms that have synergistic efficacy when administered consecutively with said ligands, such as chemotherapeutic agents and or radiation therapy.
Owner:MERCK PATENT GMBH
Isolated organ perfusion combination therapy of cancer
InactiveUS20110165150A1Reduce morbidityReduce frequencyHeavy metal active ingredientsEnergy modified materialsLymphatic SpreadCombined Modality Therapy
The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered together with said ligands, such as chemotherapeutic agents and / or radiation therapy, in isolated organ perfusion. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone.
Owner:MERCK PATENT GMBH
Biphenyl and biphenyl-analogous compounds as integrin antagonists
The present invention relates to biphenyl and biphenyl-analogous compounds, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of pharmaceutical compositions for the treatment and prophylaxis of cancer, arteriosclerosis, restenosis, osteolytic disorders such as osteoporosis and ophthalmic diseases. The compounds according to the invention have formula (1) wherein R<1>, R<2>, U, V, A, B, W, R<3>, C and R<4> have the meaning as defined in the claims.
Owner:BAYER AG
Specific therapy and medicament using integrin ligands for treating cancer
InactiveUS20100190957A1Increase volumeIncrease the number ofInorganic active ingredientsImmunoglobulinsLymphatic SpreadIntegrin antagonist
Owner:MERCK PATENT GMBH
Compounds αv β6 integrin antagonists
Owner:GLAXOSMITHKLINE INTPROP DEV LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com